Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Completes Vioxx-Related Cost Reduction Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck's third quarter financial results reflect an $80 mil. charge associated with the company's post-Vioxx global cost reduction program, CEO Richard Clark said during a third quarter earnings call Oct. 24

You may also be interested in...



Merck Begins Cuts With Manufacturing, More Cost Reductions To Follow

The company suggests future restructuring efforts could address R&D, marketing and sales after unveiling the first phase of its restructuring initiative.

Merck Begins Cuts With Manufacturing, More Cost Reductions To Follow

The company suggests future restructuring efforts could address R&D, marketing and sales after unveiling the first phase of its restructuring initiative.

Merck CEO Clark Brings Managed Care Expertise To Post; Gilmartin Retires

Richard Clark's appointment signals the importance Merck is placing on managed care ahead of the January 2006 start of the Medicare drug benefit. Merck also is highlighting Clark's manufacturing expertise, but acknowledges he will rely on Merck Research Labs President Peter Kim for advice on R&D strategy.

Related Content

Topics

UsernamePublicRestriction

Register

PS061149

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel